Literature DB >> 23769805

Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.

Antonio Cerasa1, Maria Salsone, Maurizio Morelli, Pierfrancesco Pugliese, Gennarina Arabia, Cecilia M Gioia, Fabiana Novellino, Aldo Quattrone.   

Abstract

PURPOSE: Recently, we demonstrated that PD patients with levodopa-induced dyskinesias are characterized by neuroanatomical and functional changes involving the prefrontal cortex. When compared with non-dyskinetic PD patients, dyskinetic PD patients showed increased volume of the inferior frontal cortex and a dysfunctional imbalance between this region and the supplementary motor area during motor task. In the current study, we investigated the impact of age at onset of the disease on the neuroanatomical characteristics of dyskinetic patients, because it is well known that early-onset PD patients usually develop dyskinesias sooner with respect to late-onset PD.
METHODS: Whole-brain voxel-wise investigations of gray matter volume and cortical thickness were carried out in dyskinetic (n = 33), non-dyskinetic PD patients (n = 33) and in age-sex-matched healthy controls (n = 40). Neuroimaging analyses were performed separately according to the age at onset (early < 50 y > late).
RESULTS: Independent of age at onset, dyskinetic PD patients showed altered morphology in the inferior frontal cortex when compared with non-dyskinetic patients. Moreover, additional significant abnormalities emerged in the early- and late-onset PD patients when compared to controls. In fact, early-onset dyskinetic patients showed increased volume in a large cluster of the midbrain encompassing substantia nigra and red nucleus, whereas late-onset dyskinetic patients were characterized by abnormal gray matter increase in the supplementary motor area. DISCUSSION: Our findings demonstrate different patterns of brain abnormalities in patients with LID according to age at onset, highlighting the role of the nigral pathology in early-onset and of the cortical pathology in late-onset patients with PD.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age at onset of disease; Inferior frontal cortex; Levodopa-induced dyskinesias; Parkinson's disease; Substantia nigra; Supplementary motor area

Mesh:

Substances:

Year:  2013        PMID: 23769805     DOI: 10.1016/j.parkreldis.2013.05.015

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease.

Authors:  Yanbing Hou; Jing Yang; Chunyan Luo; Ruwei Ou; Wei Song; Wanglin Liu; Qiyong Gong; Huifang Shang
Journal:  J Neurol       Date:  2016-07-09       Impact factor: 4.849

2.  Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.

Authors:  Alessandra Nicoletti; Giovanni Mostile; Giuseppe Nicoletti; Gennarina Arabia; Giovanni Iliceto; Paolo Lamberti; Roberto Marconi; Letterio Morgante; Paolo Barone; Aldo Quattrone; Mario Zappia
Journal:  J Neurol       Date:  2016-03-10       Impact factor: 4.849

3.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

4.  Future scenarios for levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Antonio Cerasa; Giacomo Koch; Alfonso Fasano; Francesca Morgante
Journal:  Front Neurol       Date:  2015-04-01       Impact factor: 4.003

Review 5.  Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology.

Authors:  Antonio Cerasa; Alfonso Fasano; Francesca Morgante; Giacomo Koch; Aldo Quattrone
Journal:  Front Neurol       Date:  2014-04-09       Impact factor: 4.003

6.  CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.

Authors:  Rui Gao; Guangjian Zhang; Xueqi Chen; Aimin Yang; Gwenn Smith; Dean F Wong; Yun Zhou
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

7.  Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.

Authors:  Sacnité Albarrán-Bravo; José Arturo Ávalos-Fuentes; Hernán Cortés; Marina Rodriguez-Sánchez; Norberto Leyva-García; Claudia Rangel-Barajas; David Erlij; Benjamín Florán
Journal:  Biomolecules       Date:  2019-09-01

Review 8.  Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.

Authors:  Clare J Finlay; Susan Duty; Anthony C Vernon
Journal:  Front Neurol       Date:  2014-06-12       Impact factor: 4.003

Review 9.  The Effectiveness of Transcranial Brain Stimulation in Improving Clinical Signs of Hyperkinetic Movement Disorders.

Authors:  Ignacio Obeso; Antonio Cerasa; Aldo Quattrone
Journal:  Front Neurosci       Date:  2016-01-07       Impact factor: 4.677

10.  Cortical thickness in Parkinson disease: A coordinate-based meta-analysis.

Authors:  LiQin Sheng; PanWen Zhao; HaiRong Ma; Joaquim Radua; ZhongQuan Yi; YuanYuan Shi; JianGuo Zhong; ZhenYu Dai; PingLei Pan
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.